Larimar Therapeutics Inc (LRMR) Stock Price, Quote & News

Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Industry: Biotechnology

Sector: Healthcare

Phone: 844 511 9056

Website: www.larimartx.com

Address:

Three Bala Plaza East, Suite 506, Bala Cynwyd, United States

GlobalMarketBulletin Jul. 18 at 9:06 AM

$LRMR Larimar Therapeutics Inc. (LRMR) has started its rolling FDA application for Nomlabofusp. Could this rare-disease biotech stock deliver major upside? https://globalmarketbulletin.com/what-makes-larimar-therapeutics-lrmr-a-potential-rare-disease-breakout-stock/

0 · Reply

GlobalMarketBulletin Jul. 18 at 8:25 AM

$ATAI $LRMR $SABS $VSTM $SOC Wall Street sees triple-digit upside in several of these stocks under $10. Discover the biotech, healthcare, energy, and cryptocurrency names investors are closely watching. https://globalmarketbulletin.com/10-stocks-under-10-analysts-believe-could-soar-200/

2 · Reply

twycgnb Jul. 16 at 6:41 PM

$LRMR boy when the shorts smell blood they come quick

0 · Reply

Valuetraderextraordinary Jul. 15 at 6:00 PM

$LRMR CEO must be talking to big pharma!

1 · Reply

Valuetraderextraordinary Jul. 15 at 5:59 PM

$LRMR Risk reward is insane!

0 · Reply

Valuetraderextraordinary Jul. 14 at 5:57 PM

$LRMR $7.3bn is $70 per share

0 · Reply

Bend15 Jul. 14 at 2:40 PM

$LRMR gap up from Thursday filled

0 · Reply

Valuetraderextraordinary Jul. 14 at 8:06 AM

$LRMR If Reate went for $7.3bn…what price LRMR?

1 · Reply

Valuetraderextraordinary Jul. 13 at 7:06 PM

$LRMR M&A target

0 · Reply

benjaminrobert23 Jul. 13 at 6:47 PM

$LRMR The first BLA module is already in the books. Really looking forward to the August 13 earnings call and hoping management confirms everything remains on track for the remaining BLA modules. Execution has been outstanding so far, and I think this story is still just getting started.

0 · Reply

Larimar Therapeutics director buys $167K in common stock

2026-07-02T10:05:18.000Z - 17 days ago

Larimar Therapeutics assumed with a Buy at H.C. Wainwright

2026-06-30T11:10:37.000Z - 19 days ago

Larimar Therapeutics price target lowered to $5 from $7 at Baird

2026-06-30T09:55:21.000Z - 19 days ago

Larimar Therapeutics selloff a buying opportunity, says Citi

2026-06-29T14:25:13.000Z - 20 days ago

Larimar stumbles on safety news even as BLA submission kicks off

Jun 29, 2026, 7:45 AM EDT - 20 days ago

Larimar Therapeutics Transcript: Study update

Jun 29, 2026, 7:45 AM EDT - 20 days ago

Larimar Therapeutics Press release: Study update

Jun 29, 2026, 7:45 AM EDT - 20 days ago

Larimar Therapeutics Slides: Study update

2026-06-29T10:35:06.000Z - 20 days ago

Larimar Therapeutics submits first module of rolling BLA for nomlabofusp

Jun 29, 2026, 6:30 AM EDT - 20 days ago

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich's Ataxia

Jun 26, 2026, 4:05 PM EDT - 23 days ago

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich's Ataxia

2026-05-27T09:15:57.000Z - 7 weeks ago

Larimar Therapeutics initiated with an Overweight at JPMorgan

2026-05-18T11:55:07.000Z - 2 months ago

Larimar Therapeutics price target lowered to $12 from $13 at Wedbush

2026-05-15T13:47:27.000Z - 2 months ago

Larimar Therapeutics price target lowered to $12 from $13 at Wedbush

2026-05-14T13:05:57.000Z - 2 months ago

Larimar Therapeutics reports Q1 EPS (31c), consensus (57c)

May 14, 2026, 7:00 AM EDT - 2 months ago

Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update

May 14, 2026, 7:00 AM EDT - 2 months ago

Larimar Therapeutics Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 2 months ago

Larimar Therapeutics Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 2 months ago

Larimar Therapeutics Slides: Investor presentation

Apr 30, 2026, 4:05 PM EDT - 2 months ago

Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's Ataxia

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Larimar Therapeutics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Larimar Therapeutics Proxy statement: Proxy filing

2026-03-20T12:00:20.000Z - 4 months ago

Larimar Therapeutics price target raised to $13 from $12 at Wedbush

2026-03-19T11:21:35.000Z - 4 months ago

Larimar Therapeutics reports Q4 EPS (73c), consensus (55c)

Mar 19, 2026, 7:00 AM EDT - 4 months ago

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 19, 2026, 7:00 AM EDT - 4 months ago

Larimar Therapeutics Annual report: Q4 2025

Mar 19, 2026, 7:00 AM EDT - 4 months ago

Larimar Therapeutics Earnings release: Q4 2025

Mar 11, 2026, 4:00 PM EDT - 4 months ago

Larimar Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 8:40 AM EDT - 4 months ago

Larimar Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 7:00 AM EDT - 4 months ago

Larimar Therapeutics Slides: Corporate presentation

Mar 4, 2026, 4:05 PM EST - 4 months ago

Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

2026-03-03T13:50:44.000Z - 4 months ago

Larimar Therapeutics price target raised to $12 from $11 at Wedbush

2026-02-26T02:10:10.000Z - 5 months ago

Larimar Therapeutics 20M share Spot Secondary priced at $5.00

Feb 25, 2026, 8:59 PM EST - 5 months ago

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

2026-02-25T21:43:26.000Z - 5 months ago

Larimar Therapeutics $75M Spot Secondary price range $4.75-$5.25

Feb 25, 2026, 4:01 PM EST - 5 months ago

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

2026-02-25T11:48:32.000Z - 5 months ago

Larimar Therapeutics price target raised to $14 from $12 at Citi

Feb 24, 2026, 7:00 AM EST - 5 months ago

Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026

Jan 14, 2026, 12:00 PM EST - 6 months ago

Larimar Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 7:00 AM EST - 6 months ago

Larimar Therapeutics Slides: Corporate presentation

Dec 18, 2025, 8:00 AM EST - 7 months ago

Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 5, 2025, 7:00 AM EST - 9 months ago

Larimar Therapeutics Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 7:00 AM EST - 9 months ago

Larimar Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 9 months ago

Larimar Therapeutics Earnings release: Q3 2025

Oct 16, 2025, 4:44 AM EDT - 9 months ago

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR

Oct 15, 2025, 9:30 PM EDT - 9 months ago

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR

Sep 29, 2025, 8:00 AM EDT - 10 months ago

Larimar Therapeutics Transcript: Study Update

Sep 29, 2025, 8:00 AM EDT - 10 months ago

Larimar Therapeutics Press release: Study Update

Sep 29, 2025, 8:00 AM EDT - 10 months ago

Larimar Therapeutics Slides: Study Update

Sep 29, 2025, 7:00 AM EDT - 10 months ago

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia

Sep 28, 2025, 5:00 PM EDT - 10 months ago

Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Earnings release: Q2 2025

Jul 31, 2025, 4:15 PM EDT - 1 year ago

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Jul 29, 2025, 11:50 PM EDT - 1 year ago

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

Jul 29, 2025, 4:01 PM EDT - 1 year ago

Larimar Therapeutics Announces Proposed Underwritten Public Offering

Jul 8, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Larimar Therapeutics Transcript: Status Update

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Larimar Therapeutics Press release: Status Update

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Larimar Therapeutics Slides: Status Update

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Slides: Corporate Presentation

Jun 20, 2025, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Apr 30, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Reports First Quarter 2025 Financial Results

Apr 30, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Quarterly report: Q1 2025

Apr 30, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Earnings release: Q1 2025

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Larimar Therapeutics Proxy statement: Proxy Filing

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Annual report: Q4 2024

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Earnings release: Q4 2024

Mar 10, 2025, 3:40 PM EDT - 1 year ago

Larimar Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 3, 2025, 4:05 PM EST - 1 year ago

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Jan 23, 2025, 4:05 PM EST - 1 year ago

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia

Dec 16, 2024, 8:00 AM EST - 1 year ago

Larimar Therapeutics Transcript: Study Update

Dec 16, 2024, 8:00 AM EST - 1 year ago

Larimar Therapeutics Press release: Study Update

Dec 16, 2024, 8:00 AM EST - 1 year ago

Larimar Therapeutics Slides: Study Update

Dec 16, 2024, 7:00 AM EST - 1 year ago

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

Oct 30, 2024, 7:30 AM EDT - 1 year ago

Larimar Therapeutics Slides: Corporate Presentation

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Quarterly report: Q3 2024

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Earnings release: Q3 2024

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Earnings release: Q2 2024

May 30, 2024, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia

May 20, 2024, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia

May 9, 2024, 8:00 AM EDT - 2 years ago

Larimar Therapeutics Registration statement: Registration Filing

May 9, 2024, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Earnings release: Q1 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Larimar Therapeutics Proxy statement: Proxy Filing

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Larimar Therapeutics Proxy statement: Proxy Filing

Mar 14, 2024, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Mar 14, 2024, 12:00 PM EDT - 2 years ago

Larimar Therapeutics Earnings release: Q4 2023

Mar 14, 2024, 12:00 PM EDT - 2 years ago

Larimar Therapeutics Annual report: Q4 2023

Mar 11, 2024, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia

Mar 6, 2024, 4:05 PM EST - 2 years ago

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 14, 2024, 6:15 AM EST - 2 years ago

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

Feb 12, 2024, 7:00 AM EST - 2 years ago

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

Nov 14, 2023, 7:00 AM EST - 2 years ago

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Nov 14, 2023, 7:00 AM EST - 2 years ago

Larimar Therapeutics Quarterly report: Q3 2023

Nov 14, 2023, 7:00 AM EST - 2 years ago

Larimar Therapeutics Earnings release: Q3 2023

Nov 1, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

Oct 3, 2023, 4:05 PM EDT - 3 years ago

Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

Aug 31, 2023, 4:05 PM EDT - 3 years ago

Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Larimar Therapeutics Quarterly report: Q2 2023

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Larimar Therapeutics Earnings release: Q2 2023

Jul 25, 2023, 7:00 AM EDT - 3 years ago

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial

Jul 17, 2023, 4:05 PM EDT - 3 years ago

Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

Jun 21, 2023, 4:05 PM EDT - 3 years ago

Larimar Therapeutics Set to Join Russell 3000® Index

May 15, 2023, 7:00 AM EDT - 3 years ago

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial's 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich's Ataxia and First Quarter 2023 Financial Results

May 15, 2023, 7:00 AM EDT - 3 years ago

Larimar Therapeutics Quarterly report: Q1 2023

May 15, 2023, 7:00 AM EDT - 3 years ago

Larimar Therapeutics Earnings release: Q1 2023

Apr 11, 2023, 8:00 AM EDT - 3 years ago

Larimar Therapeutics Proxy statement: Proxy Filing

Mar 28, 2023, 4:05 PM EDT - 3 years ago

Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days

Mar 14, 2023, 12:00 PM EDT - 3 years ago

Larimar Therapeutics Earnings release: Q4 2022

Mar 14, 2023, 12:00 PM EDT - 3 years ago

Larimar Therapeutics Annual report: Q4 2022

Mar 14, 2023, 7:00 AM EDT - 3 years ago

Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results

GlobalMarketBulletin Jul. 18 at 9:06 AM

0 · Reply

GlobalMarketBulletin Jul. 18 at 8:25 AM

2 · Reply

twycgnb Jul. 16 at 6:41 PM

$LRMR boy when the shorts smell blood they come quick

0 · Reply

Valuetraderextraordinary Jul. 15 at 6:00 PM

$LRMR CEO must be talking to big pharma!

1 · Reply

Valuetraderextraordinary Jul. 15 at 5:59 PM

$LRMR Risk reward is insane!

0 · Reply

Valuetraderextraordinary Jul. 14 at 5:57 PM

$LRMR $7.3bn is $70 per share

0 · Reply

Bend15 Jul. 14 at 2:40 PM

$LRMR gap up from Thursday filled

0 · Reply

Valuetraderextraordinary Jul. 14 at 8:06 AM

$LRMR If Reate went for $7.3bn…what price LRMR?

1 · Reply

Valuetraderextraordinary Jul. 13 at 7:06 PM

$LRMR M&A target

0 · Reply

benjaminrobert23 Jul. 13 at 6:47 PM

0 · Reply

jsmerka Jul. 13 at 5:54 PM

$LRMR Rollercoaster 🎢

0 · Reply

WILLWISH Jul. 12 at 7:37 PM

$LRMR FA affects a relatively small patient population but has significant medical need and potential premium pricing..

0 · Reply

SHVR89 Jul. 12 at 2:51 AM

$LRMR

0 · Reply

OldManLogan Jul. 11 at 1:35 PM

$LRMR THIS is why I'm here... superior treatment to a drug that sold for $7.3

1 · Reply

i_am_the_walrus_67 Jul. 11 at 12:54 AM

$LRMR Skyclarys v Nomlabofusp mFARS over time. Doesn’t take a genius to figure out the trend here. Skyclarus only slows disease progression. Nomlabofusp patients IMPROVE, even after 1 year. Of course, small samples. But also, the science backs nomla attacking the root cause.

0 · Reply